Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition
Titel:
Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition
Auteur:
Rimassa, Lorenza Bozzarelli, Silvia Pietrantonio, Filippo Cordio, Stefano Lonardi, Sara Toppo, Laura Zaniboni, Alberto Bordonaro, Roberto Di Bartolomeo, Maria Tomasello, Gianluca Dadduzio, Vincenzo Tronconi, Maria Chiara Piombo, Chiara Giordano, Laura Gloghini, Annunziata Di Tommaso, Luca Santoro, Armando